Does BPC 157 Cause Cancer?

Your body is already running the exact pathway that makes BPC-157 controversial, and it runs it every time you get a cut.

When tissue gets damaged, your body needs to rebuild the blood vessels that supply that tissue, and it does this through a signaling molecule called VEGF, which stands for vascular endothelial growth factor and what it does is tell cells to build new blood vessels. The cells that receive that signal have receptors on their surface called VEGFR2, and when VEGF binds to those receptors, the construction process begins. More receptors means more sensitivity to the signal, which means faster and more robust vessel growth. That is the repair system working exactly as it should.

BPC-157 works through something called VEGFR2 upregulation, which means it increases the number of those receptors on your cells so the repair signal lands harder and triggers a stronger response. A 2017 study using a rat hind limb ischemia model found that BPC-157 activated the VEGFR2-Akt-eNOS signaling pathway and increased vessel density in the ischemic tissue, which is exactly what you want when you are trying to heal damaged muscle or restore circulation to injured tissue. The healing mechanism is real. That part is not in dispute.

The problem is that tumors use the same blueprint.

When a solid tumor grows beyond a certain size, it runs out of the passive nutrient diffusion that kept it alive in its early stages, so it starts sending out VEGF signals to recruit blood vessels of its own. Once it builds that supply network, it can grow aggressively and eventually seed cells elsewhere. This process is called angiogenesis, and it is so central to tumor survival that an entire class of cancer drugs, anti-angiogenic therapies, works specifically by blocking VEGF signaling to starve tumors of their blood supply. You block the signal, you cut the supply line, you slow the tumor.

So the concern about BPC-157 is structurally straightforward. If it upregulates VEGFR2 and amplifies the VEGF signaling pathway, and if a person has a tumor they do not know about, could BPC-157 be accelerating the very process those cancer drugs are trying to shut down? That is not a fringe question. It follows directly from the mechanism.

Now here is what the actual evidence looks like, and this is where you have to hold the uncertainty honestly.

There is one published study that tested BPC-157 directly against cancer cells. It was a 2004 conference abstract looking at the SK-Mel-1 human melanoma cell line, and it found that BPC-157 reduced the total S-phase fraction, which is a measure of active cell division, by up to 55% compared to controls. That sounds like a meaningful finding in the opposite direction of the concern. If anything, it seemed to slow the cancer cells down rather than accelerate them.

But that study has never been independently replicated in over 20 years. It was a conference abstract, not a full peer-reviewed paper, and it came from a research group closely affiliated with the scientists who have championed BPC-157 broadly. A 2025 published commentary noted explicitly that no in vivo data exist showing BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis in a living organism. The melanoma cell line result, unreplicated and conducted in a dish, is the entirety of the direct cancer evidence in either direction.

That same 2025 commentary raised something else worth noting. BPC-157 also activates something called FAK-paxillin signaling, and FAK-paxillin is a known pathway in cancer cell invasion, the process by which cancer cells break away from a primary tumor and migrate to other tissues. This does not prove harm either, but it adds another theoretical mechanism that has not been tested and cannot be dismissed.

This is the position the evidence actually puts you in. You have a plausible pro-tumor mechanism through VEGFR2 upregulation. You have a single unreplicated cell-study showing what might be a protective effect. You have a second plausible pro-invasion mechanism through FAK-paxillin. And you have zero studies in living organisms with actual tumors. A 2025 narrative review concluded that BPC-157 should be considered investigational until well-designed human trials are conducted, which is not a condemnation but it is also not a clearance.

The practical framework that follows from this is not complicated.

If you have no history of cancer, no active diagnosis, and no known precancerous conditions, the theoretical risk from the VEGF mechanism is real but unquantified, and there is no direct evidence it manifests in practice. That is a personal risk calculation you make with incomplete information, the same way you make many decisions in health. The theoretical concern is worth knowing, not worth panicking over, but also not worth dismissing.

If you have active cancer, a history of cancer, or a known precancerous condition, the combination of an unresolved pro-angiogenic mechanism and zero safety data in tumor-bearing organisms is enough to warrant avoiding BPC-157 until the research catches up. The absence of evidence is not evidence of safety when the mechanism gives you a specific reason to be cautious.

And none of this substitutes for the screenings that would tell you whether a tumor exists in the first place.

The deeper thing to understand here is that the same biological systems that heal you are often the ones that disease hijacks. VEGF signaling is not a flaw in your body, it is a feature, and it is a feature that cancer learned to exploit. Any compound that amplifies those systems is operating in territory where the benefit and the risk share the same pathway, and that is exactly the kind of situation where the absence of long-term human data matters more, not less.

---

References

1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. Study conditions: Rat hind limb ischemia model and human umbilical vein endothelial cell cultures. Did not test tumor models. Finding: BPC-157 increased VEGFR2 expression and activated the VEGFR2-Akt-eNOS signaling pathway, increasing vessel density in ischemic tissue.
2. Radeljak S, Seiwerth S, et al. BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. Melanoma Research. 2004;14(4):A14-A15 (conference abstract). Study conditions: In vitro, SK-Mel-1 human melanoma cells at 2ng and 10ng concentrations. Authored by Sikiric-affiliated researchers. Never independently replicated. Finding: BPC-157 lowered total S-phase fraction (cell division) up to 55% in SK-Mel-1 melanoma cells compared to controls.
3. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18(10):1451. Published commentary (not original research). Finding: No published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis. The Radeljak 2004 study remains unreplicated. BPC-157 activates FAK-paxillin signaling, a known pathway in cancer cell invasion.
4. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. Finding: BPC-157 should be considered investigational until well-designed human trials are conducted and published.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness